Clin2
NCT07500285Possibly a fitNot yet recruiting

Y-90 FAPI therapy for advanced non-small cell lung cancer

Non-Small Cell Lung CancerMetastatic Lung Carcinoma

Part of Cancer, Lungs & breathing clinical trials.

This trial tests a new radioactive treatment (Y-90 FAPI) for people with non-small cell lung cancer that has spread and hasn't responded to standard therapies. The treatment targets cancer cells specifically to try to shrink tumors.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
10 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You have non-small cell lung cancer that has spread to other parts of your body.
  • You have already tried all standard treatments and they stopped working or you couldn't tolerate them.
  • A special scan (FAPI PET/CT) shows that your tumors absorb a lot of the tracer, meaning the treatment can target them.
  • You are in generally good health (able to care for yourself and up and about more than half of the day).
  • Your blood counts and liver/kidney function tests are within a safe range.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06107608Recruiting
Scan for tumors in lung cancer patients on immunotherapy

This study uses a special type of PET scan to look at specific cells in non-small cell lung cancer tumors that might help doctors understand how well immunotherapy treatments are working. If you are about to start immunotherapy for advanced lung cancer, you may be able to join.

Brussels
NCT07689643Recruiting· Early Phase 1
Radioactive drug plus immunotherapy for FAP-positive lung cancer

This trial tests a new treatment that uses a radioactive medicine called [177Lu]Lu-RTX-2358 combined with immunotherapy (a type of drug that helps your immune system fight cancer). It is for people with advanced non-small cell lung cancer whose tumors have a specific marker called FAP.

Wuhan, Hubei
NCT06937112Recruiting
A new scan for early detection of certain cancers

This trial tests a new imaging agent (18F-FAPI) to see if it can help find tumors early in people with lung, thyroid, pancreatic, melanoma, or neuroendocrine cancers.

Nanjing, Jiangsu
NCT07135128Recruiting· Phase 1
Study of a radioactive drug for advanced solid tumors

This trial tests a new radioactive drug (225Ac-FAPI-XT) for people with advanced solid tumors that have stopped responding to standard treatments. It targets a protein called FAP found on many cancer cells, which may help deliver radiation directly to the tumor.

Jinan, Shandong
NCT06503146Recruiting· Phase 2
New imaging tracer for detecting various cancers

This trial tests a new imaging agent, [18F]FAPI-74, which might help detect certain cancers more clearly. The scan looks for a protein called fibroblast activation protein (FAP) that is often found in tumors. If you have one of the listed cancers and are about to start treatment, this study could help doctors see where the cancer is and how it responds to therapy.

Bethesda, Maryland
NCT07014254Not yet recruiting
Lu-177 CTR-FAPI for advanced digestive cancers

This trial tests a new radioactive drug that targets a protein called FAP on cancer cells. It is for people with advanced stomach, pancreas, colon, bile duct, or esophageal cancers that have spread and show high FAP levels on a special scan.

Xi'an, Shaanxi

Hear when a new Non Small Cell Lung Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.